Drug decision

• Health & Medicine

New treatment option made available for advanced womb cancers

Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer

8 March 2024

• Health & Medicine

NHS offers first drug targeting advanced breast cancers driven by BRCA gene mutations

Around 300 people in England can receive talazoparib, which can stop advanced breast cancers with BRCA gene mutations growing for longer. Around 300 people in England can receive talazoparib, which can stop advanced breast cancers with BRCA gene mutations growing for longer.

25 January 2024

• Health & Medicine

Durvalumab immunotherapy recommended for advanced bile duct cancers in England and Scotland

The immunotherapy durvalumab (Imfinzi) is now available as a first treatment for advanced biliary tract cancers in England and Scotland. The immunotherapy durvalumab (Imfinzi) is now available as a first treatment for advanced biliary tract cancers in England and Scotland.

30 November 2023

• Health & Medicine

Thousands of women offered anastrozole to help prevent breast cancer

The MHRA has licensed anastrozole as a way to prevent breast cancer in almost 300,000 women. Our trial showed that it can halve their risk. The MHRA has licensed anastrozole as a way to prevent breast cancer in almost 300,000 women. Our trial showed that it can halve their risk.

7 November 2023

• Health & Medicine

First immunotherapy approved for cervical cancer in England and Scotland

The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland. The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland.

16 May 2023

• Health & Medicine

Olaparib approved for 800 prostate and breast cancer patients in England

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

11 April 2023

• Health & Medicine

NICE recommends pembrolizumab for 1,600 more people with breast cancer

The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales. The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

14 November 2022

• Health & Medicine

New treatment for Waldenstrom’s macroglobulinaemia in England

1 October 2022

• Health & Medicine

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

13 September 2022

• Health & Medicine

New targeted treatment for early breast cancer could reduce risk of relapse

A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning. A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning.

21 July 2022

• Health & Medicine

NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia

Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England

23 May 2022

• Health & Medicine

Triple negative breast cancer drug given initial ‘no’ for NHS in England

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer. Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

8 April 2022